Skip to main content

AIHC Capital Management Ltd

13F filer · CIK 0002103725
Reported Aug 13, 2026
Net seller this quarter
13F portfolio value$104MU.S. long equity reported on 13F
Positions40 new · 1 closed
Net flow last quarter-$84.4MBuys minus sells
Top 10 positions weight100.0%Concentration

Holdings

13F · last 4 quarters free
Scroll for earlier quarters
CompanyValue% of portfolio% of companyPOSITION CHANGE qoq %First reported
Q2 2026Reported Aug 13, 20264 positions
RVMDRevolution Medicines, Inc.$56.8M54.46%0.14%-63.4%Q4 2025
ORICOric Pharmaceuticals, Inc.$41.5M39.77%3.69%+55.7%Q1 2026
NBPNovaBridge Biosciences$5.61M5.38%1.08%+27.2%Q4 2025
KRROKorro Bio, Inc.$399K0.38%0.21%Not reportedQ4 2025
Q1 2026Reported May 8, 20265 positions
RVMDRevolution Medicines, Inc.$80.6M67.37%0.41%-7.9%Q4 2025
ORICOric Pharmaceuticals, Inc.$31.2M26.04%2.38%NewQ1 2026
NBPNovaBridge Biosciences$5.57M4.65%0.85%+446.6%Q4 2025
COGTCogent Biosciences, Inc.$1.98M1.65%0.03%-48.6%Q4 2025
KRROKorro Bio, Inc.$343K0.29%0.21%Not reportedQ4 2025
Q4 2025Reported Feb 5, 20266 positions
RVMDRevolution Medicines, Inc.$71.7M67.21%0.46%NewQ4 2025
PTGXProtagonist Therapeutics, Inc$16.6M15.54%0.30%NewQ4 2025
AVBPArriVent BioPharma, Inc.$13M12.16%1.52%NewQ4 2025
COGTCogent Biosciences, Inc.$3.55M3.33%0.06%NewQ4 2025
NBPNovaBridge Biosciences$1.65M1.54%0.16%NewQ4 2025
KRROKorro Bio, Inc.$242K0.23%0.32%NewQ4 2025
Premium opens every quarter this fund has filed

Not investment advice. We make every effort to keep the information on SpoorBase accurate, but errors may occur. SpoorBase does not guarantee the accuracy or completeness of any data, and any use of the information is at the user’s sole responsibility. Valuation multiples are calculated by SpoorBase and may contain errors. See Disclosures. © 2026 SpoorBase. All rights reserved.